| Name | Title | Contact Details |
|---|
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). Millions of patients do not see effective relief from drugs, yet decline to undergo an invasive surgical procedure with high risk of side effects such as sexual dysfunction.
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
ARMUS Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Vbm Medical Inc is a Noblesville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ConvaTec is a global medical products and technologies company with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Our brands include AQUACEL® advanced wound dressings, which form a gel on contact with wound fluid, creating an optimal environment for wound healing. ConvaTec has more than 9,000 employees with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. We are owned by Nordic Capital and Avista Capital Partners.